Heart experts fear Trump’s FDA is ‘ignoring decades of evidence’ as it authorizes new nicotine pouches

August 8, 2026 - 03:56

The Food and Drug Administration has given the green light to four new flavored nicotine pouches, a decision that regulators say could help adult smokers transition away from cigarettes. But the move is drawing sharp criticism from heart health experts who argue the agency is sidestepping long-standing scientific evidence.

The American Heart Association issued a statement expressing serious reservations, saying "key questions" about the products' long-term health effects remain unanswered. The group specifically pointed to the lack of data on cardiovascular risks, particularly for young adults who might be drawn to the flavors.

"By authorizing these products, the FDA is ignoring decades of evidence linking nicotine to heart disease, high blood pressure, and stroke," the association said. "We are concerned that these pouches will create a new generation of nicotine users rather than simply serving as a bridge for existing smokers."

The FDA, for its part, maintains that the pouches meet a public health standard because they deliver nicotine without the tar and carbon monoxide found in combustible cigarettes. The agency noted that the products are not approved for youth and will be subject to strict marketing restrictions.

Still, critics point out that the authorization comes at a time when the FDA's leadership is under pressure from the Trump administration to take a more industry-friendly approach. Some public health officials worry that political influence is overriding scientific review.

The pouches, which are placed between the gum and lip, come in flavors like mint and citrus. While they are less harmful than smoking, experts stress that they are not harmless. Nicotine itself is addictive and can damage blood vessels, raising the risk of heart attacks even in otherwise healthy people.

The heart association is calling on the FDA to reverse its decision and require more rigorous studies before any further approvals. For now, the four products will remain on shelves, leaving consumers to weigh the potential benefits against the unknown risks.